Perrigo Company plc Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Perrigo Company plc (PRGO) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $15.20 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $15.20M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $18.00M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $17.90M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $21.40M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $15.20M 10-K · filed 2026-02-26 |
| 2024-12-31 | $18.00M 10-K · filed 2026-02-26 |
| 2023-12-31 | $17.90M 10-K · filed 2025-02-28 |
| 2022-12-31 | $21.40M 10-K · filed 2024-02-27 |
| 2021-12-31 | $27.50M 10-K · filed 2023-02-28 |
| 2020-12-31 | $24.50M 10-K · filed 2022-03-01 |
| 2019-12-31 | $23.20M 10-K · filed 2021-03-01 |
| 2018-12-31 | $19.60M 10-K · filed 2020-02-27 |
| 2017-12-31 | $16.20M 10-K · filed 2019-02-27 |
| 2016-12-31 | $18.10M 10-K · filed 2018-03-01 |
| 2015-12-31 | $20.60M 10-K · filed 2018-03-01 |
| 2015-06-27 | $14.30M 10-K · filed 2017-05-22 |
| 2014-06-28 | $14.30M 10-KT · filed 2016-02-25 |
| 2013-06-29 | $13.20M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |